top of page

PROGRAMME

Wed

Wednesday 19 March

12:30-13:30
Registration

13.30-14.30
Opening keynote
Chair: François Moreau Gaudry, Oumeya Adjali

​

13:30 Welcome

​

13:45 Gregory Newby, John Hopkins University
INV01  Title TBC

​

14.30-16.30 
Session 1: Advances and challenges for gene editing technology
Chairs:

​

​14:30 Anna Cereseto, University of Trento

INV02: Title TBC

 

15:00 Aurélie Bedel, University of Bordeaux, INSERM U1312

INV03: Challenges for CRISPR-Cas9 genotoxicity: detection and prevention

​

OR01, OR02, OR03, OR04

16:30-17:00
Coffee Break

17.00-19.00
Session 2: Preclinical and clinical gene editing for gene therapy

Chairs: 

​

17:00 Matthew Porteus, Stanford University

INV04 : Title TBC

​

​17:30 Mario Amendola, Genethon, Evry​

INV05  Title TBC

​​

​18:00 Paula Rio, Ciemat/Ciberer, Madrid​

INV06  Title TBC

​

OR05, OR06

20:00
Party at Mama Shelter

Thu

Thursday 20 March

08:30-09:00
Registration 

09.00-10.45
Session 3: AAV and lentiviral vectors for gene therapy
Chair: 


Alessio Cantore, SR-Tiget, Milano
INV07 Title TBC

 
Hildegard Büning, Hannover Medical School
INV08  Title TBC

 

OR07, OR08, OR09

10:45-11:15
Coffee Break

11.15-12.45
Session 4: Cancer Therapy I - Immunotherapy and CAR-T cells
Chair: 
 

11:15 Naomi Taylor, Université de Montpellier, NIH
INV09  Title TBC
11:45 Els Verhoeyen, University of Nice
INV10 

 

OR10, OR11​

12:45-13:45
Lunch

13:45-14:45
Poster session

14.45-16.45
Session 5: Disease model : IPSc and organoids cell therapy
Chair: 


Olivier Goureau, Institut de la Vision, Paris

INV11 Retinal organoids for modeling inherited retinal diseases and developing new therapeutic strategies

 
Jens Schwamborn, University of Luxemburg
INV12  Patient specific midbrain organoids and assembloids for in vitro disease modeling

 

Saverio Tedesco, UCL London​

INV13  Engineering human skeletal muscle for advanced modelling of neuromuscular diseases and gene therapies.

​

OR12, OR13

16:45-17:15
Coffee Break

17.15-18.45

Session 6: Gene therapy for genetic diseases

Chair: 
Françoise Piguet, ICM, Paris
INV14 Gene therapy of lysosomal storage disorders

​

Matthias Titeux, Institut Imagine, Paris
INV15 Title TBC

​​

OR14, OR15

18:45-20:15
Poster session 2

Fri

Friday 21 March

08:30-09:00
Registration 

09.00-10.30
Session 7: Cancer therapy II
Chair: 
 

09:00  Mario Squadrito, SR-Tiget, Milan

INV16 In vivo liver macrophage engineering for cancer immunotherapy

​

09:30 Laurie Menger, Institut Gustave Roussy
INV17  In vivo genome-wide CRISPR screens for advanced T cell therapy

 

OR16, OR17

10:30-11:00
Coffee Break

11.00-12.45
Session 8: Non-viral vector / nanotechnology for gene editing
Chair: 
Jacob Giehm Mikkelsen, Aarhus University
INV18  Title TBC

​

Zoltan IvicsFraunhofer Institute for Cell Therapy and Immunology, Leipzig
INV19  Title TBC

​​

OR18, OR19, OR20

12:45-14:00
Lunch and posters

14.00-15.45 
Session 9: Innovative approaches
Chair: 


14:00 Jean-Luc Perfettini, Gustave Roussy, Paris
INV20  Title TBC

​

14:30 Guy LenaersUniversité d'Angers
INV21  Title TBC

​​

OR21, OR22, OR23

16.00-16.45

Session 10: Closing keynote

Chair: 
 

16:00 Alessandro Aiuti, SR-Tiget, Milan
INV22 Title TBC

16:45-17:00
Poster and oral presentation awards

bottom of page